Turkoglu 2015

Methods	Prospective study, treatment in the better‐seeing eye
Participants	Country: Turkey Number of people randomised: 70 participants (35 ranibizumab, 35 grid laser) Average age: 64.6 ± 8.2 years ranibizumab; 63.8 ± 7.4 years laser Sex: 21% male ranibizumab, 18% male laser Inclusion criteria: evidence of CSME by means of FFA at least 6 months of follow‐up no other systemic or ocular disease that might affect vision Exclusion criteria: participants with a history of intravitreal injection and laser photocoagulation for proliferative diabetic retinopathy or CSME participants with vitreous haemorrhage present at the time of recruitment or vitreous haemorrhage which developed after enrolment
Interventions	Focal or grid laser photocoagulation treatment was performed in 35 participants and laser settings, including power, spot size, duration and number of burns, were recorded 35 participants received initial injection of ranibizumab 0.5 mg/0.05 mL. All participants of both groups received treatment in their better‐seeing eye. After the induction phase, the intravitreal injections were administered if any of the following changes were observed: presence of visual acuity loss; persistent or recurrent subretinal or intraretinal fluid.
Outcomes	Group comparisons of absolute scores and mean changes from baseline scores at 6‐month visit were performed using analysis of the Turkish version of VFQ‐25; it has modifications to adjust for Turkish culture and lifestyle.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No data available
Allocation concealment (selection bias)	Unclear risk	No data available
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No data available
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No data available
Incomplete outcome data (attrition bias) All outcomes	Low risk	No loss to follow‐up reported
Selective reporting (reporting bias)	Unclear risk	No specific statement nor protocol available
Other bias	Low risk	No other bias identified
Overall risk of bias	Unclear risk	Most items not reported